STK11 Gene clinical trials
17 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
- A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
- Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Pancreatic Cancer Screening for At-risk Individuals
- Pancreatic Cancer Early Detection Consortium
- Pancreas Registry and High Risk Registry
- Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
- Prospective Familial Registry for Pancreas Research
- Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “STK11 Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.